Frontlight ResearchEarly access
CompletedPhase 3
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
Key facts
- Who runs it
- Bioaraba Health Research Institute
- Where
- Spain9 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 390 people enrolled
- Started
- 7 Oct 2022
- Ended
- 1 Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- N-acetylcysteine
- Record updated
- 16 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Men and women
- Age from 18 to 75 years
- Patients with acute alcoholic hepatitis according to AASLD criteria or compatible liver histology
- Maddrey score> = 32
- Acceptance of participation through written informed consent
Who cannot take part
- Concomitant uncontrolled diseases (HBV, HCV, HIV, TB, DILI, HCC or acute pancreatitis)
- Any cause of jaundice: acute hepatitis, positive HIV serology, biliary-pancreatic pathology, hemolytic anemia
- Allergy or intolerance to N-acetylcysteine and / or corticosteroids
- Any disease whose life expectancy is less than 12 months
- Patients with uncontrolled active infection
- Uncontrolled upper gastrointestinal bleeding
- Multiple organ failure or shock
- Acute kidney disease with creatinine> 2.5 mg / dL
- Hepatocarcinoma
- Portal cavernomatosis
- Portal cavernomatosis
- Patients with nitroglycerin and / or carbamazepine-based treatments
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive corticosteroids.
The 2 groups in the trial
- CorticosteroidsExisting treatment, for comparison
Corticosteroids following Standard Clinical Practice
Treatment: N-acetylcysteine
- Corticosteroids + N-acetylcysteineTreatment being tested
Corticosteroids following Standard Clinical Practice plus N-acetylcisteine
Treatment: N-acetylcysteine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 16 October 2026